ArticleCureus2025
Botulinum Toxin for the Treatment of Chronic Notalgia Paresthetica: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Notalgia paresthetica (NP) is a chronic sensory neuropathy characterized by localized pruritus and dysesthesia of the upper back, typically resulting from thoracic dorsal rami entrapment. Treatment is often challenging, with many patients experiencing only partial relief from topical corticosteroids, antihistamines, or intralesional injections. We present the case of a middle-aged female with treatment-resistant NP who failed multiple therapies, including topical and intralesional triamcinolone. After experiencing persistent daily discomfort affecting her quality of life, she was treated with targeted intramuscular onabotulinumtoxinA (Botox) injections to the symptomatic area. The patient reported substantial improvement in symptoms following the second round of injections. This case highlights the potential role of botulinum toxin as an effective therapeutic option in managing refractory NP, particularly in patients who do not respond to standard therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.